Advertisement
Advertisement
U.S. markets close in 1 hour 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.6097-0.0302 (-4.72%)
As of 02:18PM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • j
    joe
    wow, I bought this 3/21 for 8.23 because the street said it was a great buy. Now they say sell at 0.62. Down 1200 bucks and now worth $80. Think I will ride it to the bottom.
  • A
    Andy
    It will take many yrs for this company to become profitable with revenue in single digits and net losses in double digits. It appears all this company does is research at the shareholders expense.

    Revenue from product sales was $3.8 million for the three months ended June 30, 2022, which included $3.1 million in product sales of Libmeldy and $0.6 million in product sales of Strimvelis.

    Net loss was $50.9 million for the three months ended June 30, 2022, compared to $36.6 million in the same period in 2021. The company had approximately 126.4 million ordinary shares outstanding as of June 30, 2022.
  • A
    Anonymous
    how is this trading at 1/3 of the cash balance?
  • a
    almeria
    Anyone else read (http://traderspot.club)? Just got a tip about ORTX from them.
  • R
    Ray
    I am watching this closely tomorrow. The short run up hit a wall today. If we break above .72 I see us heading to .88, some people don't believe chart reading, but that is what I see. If we break above .88 then right to 1.25.
    Bullish
  • R
    Rafa
    Now that we have a procedure that can help young with MLD hopefully the medical community begins more frequent testing as soon as the warning signs arise. It will allow Orchard to save more lives.
  • L
    LEZA
    Guys, check out (http://Achieverspot.tech). They have been crushing it lately while ORTX barley does anything at all.
  • B
    BRISENTINE
    I don't think that ORTX has another 10% in gains in it. Looks pretty bad here. I actually found (http://Achieverspot.tech) the other day and their stocks are way better...
  • e
    eric
    Soooo oversold
  • R
    Ray
    There was some nice buying around .62 ~.63 this morning. Should continue to move up, someone is buying some decent size blocks.
    Bullish
  • R
    Rafa
    Since taking the reigns, Bobby Gaspar has made some very smart moves. Backing out of the manufacturing facility in CA, steering their technology towards more mainstream indications, consolidating the Next BLA for multiple countries and pushing for advanced testing for MLD. All of these moves will conserve cash or increase revenue. He’s a very smart guy and will turn Orchard around. They are no longer a pre revenue biotech.
  • A
    Andy
    Whether the market is green or red there is no interest in this company and stock.
  • R
    Ray
    Next resistance is around .72 .73, look at the charts and volume. Something is up on a positive note.
    Bullish
  • C
    Clint
    Going run… load up!
  • j
    joe
    Barklays lowered their price target to $4.00 for this junk. If it ever went that high I would still have lost 50% of my investment.
  • w
    wallstboss
    (ADIL) $1.22 --MCap $29 mil --- Blockbuster Phase 3 results imminent ( in June) = $$$$$$$$$$$$$$$$
    "Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of
    Alcohol Use Disorder; on track to report Phase 3 results in the current quarter"

    #+#+
  • R
    Rafa
    It’s pretty amazing that Orchard has been beaten down to the $.40s. They have not at all been rewarded for their accomplishments to date. We all realize that MLD is a very rare desease and may never provide the revenue to turn Orchard into a great investment. But Limeldy works and it may provide a normal life for very young kids suffering from MLD. Hopefully more countries approve its use and provide the reimbursement necessary for Orchard to continue.
    The big question becomes can Orchard utilize their stem cell knowledge on more common indications such as Crones and Dementia. They certainly explain HSC’s mechanism of action in great detail. Certainly Orchard’s management believes HSC will crossover as does RA Capital, Federated Hermes and FMR. They have enough cash to get us into 2024 to find out. It looks like a great bet!! Thoughts?
  • A
    Asyan
    Halloo, any news please?
  • T
    Tony
    The FDA has granted Orchard Therapeutics' (NASDAQ:ORTX) OTL-200 its Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of early-onset metachromatic leukodystrophy (MLD), a rare hereditary disorder characterised by accumulation of fats called sulfatides.
    Bullish
  • K
    Kyle
    Data is out. Positive results as far as I’m reading. Tons of info on Tekada and Denali, among many others. Really good stuff. If you have a college email you can access the info through the conference website. Take a gander.
Advertisement
Advertisement